GoKawiil
Tech News
A publisher correction has been issued for the study 'Sleep chart of biological ageing clocks in middle and late life.' The correction notice itself does not detail the specific errors being fixed, only confirming that a correction to the original publication has been made.
Novo Nordisk tested blood from over 10,000 trial participants using proteomic clocks and found signs that its weight-loss drug slowed biological aging, including up to a 4-year shift in a clock measuring heart protein age. Eli Lilly ran a smaller study on tirzepatide using epigenetic clocks that track DNA changes, and also found molecular aging appeared to slow in patients taking the drug compared to placebo.
Neuroscientist Christin Glorioso, founder of NeuroAge Therapeutics, has created a competition called Younger that pits participants against each other based on measurements of biological age. Entrants will submit samples to services such as TruDiagnostic, which uses epigenetic markers to estimate overall biological age, pace of aging, and the ages of 11 individual organ systems. Glorioso says the contest aims to educate the public about aging clocks and to build what she calls the world's most comprehensive dataset on them.
Researchers led by Jesse Poganik at Brigham and Women's Hospital transplanted young hearts into middle-aged mice and middle-aged hearts into young mice, implanting the extra organ in the neck to compare it with the original. Using three molecular 'aging clocks' to measure biological age, the team found that transplanted hearts largely took on the biological age profile of the recipient rather than retaining the age of the donor, a pattern also suggested by records from human heart transplant recipients.
Researchers testing an AI-designed anti-aging drug reported that it lowered participants' biological age, as measured by aging clocks, in every case in the trial. The drug's development leaned on artificial intelligence tools to identify compounds likely to slow or reverse aging markers in the body.
Insilico Medicine's AI-designed drug rentosertib, originally developed to treat idiopathic pulmonary fibrosis, produced unexpected reductions in biological age markers during a phase 2a trial. Researchers reanalyzed blood samples from 42 of 71 Chinese trial participants using six computational aging clocks, finding treated patients showed younger predicted ages after 12 weeks compared to placebo recipients.